Exagen Inc. (XGN)
NASDAQ: XGN · IEX Real-Time Price · USD
1.400
+0.020 (1.45%)
At close: May 3, 2024, 4:00 PM
1.470
+0.070 (5.00%)
After-hours: May 3, 2024, 7:56 PM EDT
Exagen Revenue
In the year 2023, Exagen had annual revenue of $52.55M with 15.33% growth. Revenue in the quarter ending December 31, 2023 was $13.77M with 7.23% year-over-year growth.
Revenue (ttm)
$52.55M
Revenue Growth
+15.33%
P/S Ratio
0.46
Revenue / Employee
$302,000
Employees
174
Market Cap
24.13M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
Dec 31, 2019 | 40.39M | 7.95M | 24.50% |
Dec 31, 2018 | 32.44M | 5.63M | 21.01% |
Dec 31, 2017 | 26.81M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Qilian International Holding Group | 46.47M |
Ekso Bionics Holdings | 17.91M |
Nephros | 14.24M |
Oncternal Therapeutics | 785.00K |
Aptorum Group | 431.38K |
Biora Therapeutics | 4.00K |
XGN News
- 3 days ago - Exagen to Announce First Quarter 2024 Results on May 13, 2024 - GlobeNewsWire
- 7 days ago - Exagen Inc. Announces Changes to the Board of Directors - GlobeNewsWire
- 6 weeks ago - Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results - GlobeNewsWire
- 2 months ago - Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum - GlobeNewsWire
- 2 months ago - Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 - GlobeNewsWire
- 4 months ago - Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance - GlobeNewsWire
- 6 months ago - Exagen Inc. Reports Strong Third Quarter 2023 Results - GlobeNewsWire
- 6 months ago - Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers - GlobeNewsWire